Effect of tamoxifen on the endometrium and the menstrual cycle of premenopausal breast cancer patients

International Journal of Gynecological Cancer

Volumn 19, Issue 4, 2009, Pages 667-681

  Buijs, Ciska ^a   Willemse, Pax H B ^a   De Vries, E G E ^a   Ten Hoor, Klase A ^a   Boezen, H M ^a   Hollema, Harry ^a   Mourits, Marian J E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Amenorrhea; Breast cancer; Endometrium; Estradiol and FSH; Menstrual cycle; Premenopause; Tamoxifen

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTRADIOL; FLUOROURACIL; FOLLITROPIN; TAMOXIFEN; THIOTEPA;

ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER PATIENT; COMBINATION CHEMOTHERAPY; CURETTAGE; DRUG EFFECT; DRUG MEGADOSE; ENDOMETRIAL DISEASE; ENDOMETRIUM; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTEROSCOPY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PREMENOPAUSE; PRIORITY JOURNAL; THICKNESS; TRANSVAGINAL ECHOGRAPHY; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CYCLOPHOSPHAMIDE; ENDOMETRIUM; EPIRUBICIN; ESTRADIOL; FEMALE; FLUOROURACIL; FOLLICLE STIMULATING HORMONE; HUMANS; MENSTRUAL CYCLE; MIDDLE AGED; PREMENOPAUSE; TAMOXIFEN; THIOTEPA;

EID: 67651024218     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a47cbe     Document Type: Article

References (30)

1. Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet. 2000; 355: 1869-1874.
2. Zarbo G, Caruso G, Zammitti M, et al. The effects of tamoxifen therapy on the endometrium. Eur J Gynaecol Oncol. 2000; 21: 86-88.
3. van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994; 343: 448-452.
4. Assikis VJ, Jordan VC. Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynecol Obstet. 1995; 49: 241-257.
5. Dijkhuizen FP, Brolmann HA, Potters AE, et al. The accuracy of transvaginal ultrasonography in the diagnosis of endometrial abnormalities. Obstet Gynecol. 1996; 87: 345-349.
6. Dijkhuizen FP, Brolmann HA, Oddens BJ, et al. Transvaginal ultrasonography and endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Maturitas. 1996; 25: 45-50.
7. Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol. 1991; 9: 1283-1297.
8. Cheng WF, Lin HH, Torng PL, et al. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 1997; 66: 233-237.
9. Bertelli G, Venturini M, Del Mastro L, et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat. 1998; 47: 41-46.
10. Jurjens H, Pratt JJ, Woldring MG. Radioimmunoassay of plasma estradiol without extraction and chromatography. J Clin Endocrinol Metab. 1975; 40: 19-25.
11. Speroff L, Glass RH, Kase NG, eds. Clinical Gynecologic Endocrinology and Infertility. Baltimore, MD: Williams and Wilkins; 2004: 1170.
12. Gass MS, Rebar RW, Cuffie-Jackson C, et al. A short study in the treatment of hot flashes with buccal administration of 17-beta estradiol. Maturitas. 2004; 49: 140-147.
13. Bakos O, Lundkvist O, Bergh T. Transvaginal sonographic evaluation of endometrial growth and texture in spontaneous ovulatory cycles-a descriptive study. Hum Reprod. 1993; 8: 799-806.
14. Fleischer AC, Kalemeris GC, Machin JE, et al. Sonographic depiction of normal and abnormal endometrium with histopathologic correlation. J Ultrasound Med. 1986; 5: 445-452.
15. Persadie RJ. Ultrasonographic assessment of endometrial thickness: a review. J Obstet Gynaecol Can. 2002; 24: 131-136.
16. Mourits MJ, De Vries EG, Willemse PH, et al. Ovarian cysts in women receiving tamoxifen for breast cancer. Br J Cancer. 1999; 79: 1761-1764.
17. Vosse M, Renard F, Coibion M, et al. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol. 2002; 101: 58-63.
18. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994; 343: 1318-1321.
19. Hulka CA, Hall DA. Endometrial abnormalities associated with tamoxifen therapy for breast cancer: sonographic and pathologic correlation. Am J Roentgenol. 1993; 160: 809-812.
20. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol. 1994; 170: 447-451.
21. Cohen I, Rosen DJ, Tepper R. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med. 1993; 12: 275-280.
22. Cohen I, Rosen DJ, Shapira J, et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol. 1994; 52: 185-190.
23. Buijs C, Willemse PH, Tinga DJ, et al. Side effects of therapy: case 2. Tamoxifen and uterine abnormalities. J Clin Oncol. 2004; 22: 2505-2507.
24. Shushan A, Peretz T, Mor-Yosef S. Therapeutic approach to ovarian cysts in tamoxifen-treated women with breast cancer. Int J Gynaecol Obstet. 1996; 52: 249-253.
25. McGonigle KF, Lantry SA, Odom-Maryon TL, et al. Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status. Cancer. 1996; 101: 59-66.
26. Taponeco F, Curcio C, Fasciani A, et al. Indication of hysteroscopy in tamoxifen treated breast cancer patients. J Exp Clin Cancer Res. 2002; 21: 37-43.
27. Mourits MJ, De Vries EG, Willemse PH, et al. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol. 2001; 97: 855-866.
28. Jaiyesimi IA, Buzdar AU, Decker DA, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995; 13: 513-529.
29. Gorodeski GI, Beery R, Lunenfeld B, et al. Tamoxifen increases plasma estrogen-binding equivalents and has an estradiol agonistic effect on histologically normal premenopausal and postmenopausal endometrium. Fertil Steril. 1992; 57: 320-327.
30. Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001; 19: 343-353.